APPENDIX 4D & HALF-YEAR FINANCIAL REPORT TO 30 JUNE 2026

1. DETAILS OF REPORTING PERIOD

Name of Entity	RocketDNA Ltd ("the Company")
ABN	17 618 678 701
Reporting Period	For the half-year ended 30 June 2026
Previous Corresponding Period	For the half-year ended 30 June 2025

2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

	Current $'000	Previous $'000	$ Change $'000	% change
Revenues from ordinary activities	4,998	3,326	1,670	50%
Loss after tax from ordinary activities attributable to members	(1,585)	(1,266)	(319)	25%
Loss after tax attributable to members	(1,585)	(1,266)	(319)	25%

	Amount Per Security	Franked Amount Per Security
Final Dividend	Nil	Nil
Interim Dividend	Nil	Nil
Previous Corresponding Period	Nil	Nil
Record Date for Determining Entitlements	Not Applicable	

Commentary on results:

For further information, refer to the review of operations contained in the directors' report, which forms part of the attached consolidated financial statements.

3. NET TANGIBLE ASSETS PER SHARE

	Current half year	Previous half year
Net tangible asset backing per ordinary security	0.37 cents	0.39 cents

For personal use only

4. DETAILS OF ENTITIES OVER WHICH CONTROL HAS BEEN GAINED OR LOST DURING THE PERIOD

Control gained over entities

Name of entity (or group of entities)	N/A
Date control gained	N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Consolidated profit/(loss) from ordinary activities of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

Loss of control over entities

Name of entity (or group of entities)	N/A
Date control lost	N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)	N/A
Consolidated profit/(loss) from ordinary activities of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)	N/A

5. DIVIDENDS DETAILS

No dividends has been paid or recommended to be paid for the half-year ended 30 June 2026.

6. DETAILS OF DIVIDEND REINVESTMENT PLANS

N/A

7. DETAILS OF ASSOCIATE AND JOINT VENTURE ENTITIES

N/A

8. FOREIGN ENTITIES

Details of origin of accounting standards used in compiling the report: Foreign entity accounting information is prepared and complies with International Financial Reporting Standards (IFRS).

9. AUDIT

This report has been based on accounts that have been subject to an audit review. There are no items of dispute with the auditor and the audit review is not subject to qualification.



David Morton
Chairman

18 August 2026

For personal use only

RocketDNA Ltd.

ABN 17 618 678 701

Interim Report - 30 June 2026

For personal use only

RocketDNA Ltd.
Corporate directory
30 June 2026

Directors	Mr David Morton	Chairman, Non-Executive Director
	Mr Christopher Clark	Managing Director & Chief Executive Officer
	Mr Paul Williamson	Executive Director & Chief Financial Officer
Company secretary	Mr Stephen Buckley	
Registered office	Ground Floor, 366 Scarborough Beach Road Osborne Park WA 6017 Email: contact@rocketdna.com.au	
Principal place of business	Ground Floor, 366 Scarborough Beach Road Osborne Park WA 6017	
Share register	Automic Registry Services Level 5, 191 St Georges Terrace Perth WA 6000 Email: hello@automic.com.au Web: www.automic.com.au	
Auditor	Hall Chadwick Audit (WA) Pty Ltd 283 Rokeby Road Subiaco WA 6008	
Legal Advisers (Australia)	Eaton Hall 20/210 Queen Victoria Street North Fremantle WA 6159	
Legal Advisers (South Africa)	Rodl & Partner 1 Eastgate Lane Bedfordview South Africa 2007	
Stock exchange listing	RocketDNA Ltd. shares are listed on the Australian Securities Exchange (ASX code: RKT) ASX Limited Level 40, Central Park 152-158 St Georges Terrace Perth WA 6005	
Website	Web: www.rocketdna.com/	
Corporate Governance Statement	RocketDNA Limited's Corporate Governance Statement can be viewed at: **www.rocketdna.com/corporate-governance**	

For personal use only

RocketDNA Ltd.
Directors' report
30 June 2026

The Directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of RocketDNA Ltd. (referred to hereafter as the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2026.

Directors

Name	Title	Appointed
Mr David Morton	Chairman, Non-Executive Director	28 March 2023
Mr Christopher Clark	Managing Director & Chief Executive Officer	3 December 2020
Mr Paul Williamson	Executive Director & Chief Financial Officer	22 June 2022

David Morton was appointed Chairman on 10 April 2024.

Principal activities

RocketDNA Ltd (ASX: RKT) provides autonomous drone-based geo-data and AI services to the mining, agriculture and critical asset sectors. The Company operates across Australia, Africa, Europe and North America, with BVLOS accreditation across multiple jurisdictions. Its xBot® drone-in-a-box products include SurveyBot, InspectBot and PatrolBot. Drone data is delivered through the SiteTube® platform, powered by the SiteDrive API.

Review of operations

The loss for the Group after providing for income tax and non-controlling interest amounted to $1,584,753 (30 June 2025: $1,265,872).

Financial Performance

- Revenue for the half year was $4.998m, an increase of 50% on the first half of 2026, driven by continued growth in recurring xBot® and data-services revenue, supported by the scaled BMA deployment, deeper penetration across existing customer sites, and an increasing number of xBot® systems on a paid ongoing service.
- Operating loss was $1.372m compared to $1.163m in the first half of 2025 and $1.534m in the second half of 2025.
- Management continue to exercise tight control over operating expenses, with the current period operating expenses being only 2% up on H2 2025.
- Cash balance was $2.698m, down $1.164m from 31 December 2025 $3.862m.
- $1.142m of cash has been expended on capital equipment, mainly completed xBot® units,and investment into SiteTube® and Skylink® platforms.
- Earnings before interest, tax, depreciation and amortisation (EBITDA) were a loss of $531k versus a loss of $738k in H2 2025.
- Unless otherwise stated, all figures in this report are in the Company's presentation currency, the Australian Dollar ("$").

Operational Developments

- Operational momentum continued with the completion of the manufacture, commissioning and deployment of xBot® units associated with BHP Mitsubishi Alliance, Norton Gold Fields and Sibanye Gold contracts.
- Customer engagement grew significantly during the half, particularly with new customers, communicating the ease of ordering drone-based data, building frameworks for new missions, demonstrating the value-add opportunities of different types of regular and ad hoc drone data, and delivering those missions.

For personal use only

- New users from both new and existing customers continue to be onboarded to the SiteTube® platform, allowing new sites to access the continuously developing capabilities of this platform and enabling them to better leverage the 'always available' drone capacity of their xBot®.

- Enterprise deployments expanded: Operations commenced at four enterprise customers during the half (Fenix Resources, Norton Gold Fields, Sibanye Platinum, and Whitehaven Coal converting to paid operations from 1 July). xBot® systems on a paid ongoing service rose to 24, with a further 15 in manufacture, transport, commissioning or trial.

- The first beta version of the Skylink® operating system was deployed in live operations with a Tier-1 mining customer in March, enabling centralised mission request, prioritisation and real-time tracking across multi-site operations. All enterprise customers were onboarded to Skylink® and monthly active users reached 1,000+ across Skylink® and SiteTube® product suite by 30 June 2026, with approximately 25,000 flight missions pre-booked (as at 30 June 2026)

- Software and integration: a non-binding, non-exclusive Memorandum of Understanding was signed with Deswik, part of Sandvik's Digital Mining Technologies division, to integrate xBot® survey data held on SiteTube® directly into

Corporate Changes

- Acquisition of remaining interest in RocketDNA (WA) Pty Ltd

  During the quarter, the Company acquired the remaining 40% of its Western Australian operating subsidiary, RocketDNA (WA) Pty Ltd, thereby increasing its holding from 60% to 100%. RocketDNA (WA) is an established operating subsidiary in which most of the Group's Australian revenue is recognised, and which the Company has controlled and consolidated since acquiring its initial 60% interest in September 2021. The transaction removes the 40% non-controlling interest and simplifies the Group structure; it does not change the Group's operations, customers, strategy, reported net assets, reported consolidated revenue or reported profit after tax.

  Consideration of A$1.0 million was satisfied entirely in new fully paid ordinary RocketDNA shares (no cash), priced at the 20-day volume-weighted average price to 15 June 2026 of $0.023942. The Company issued 41,767,605 shares, representing approximately 3.5% of current issued capital, within its existing placement capacity under Listing Rule 7.1, with the consideration shares held in voluntary escrow for 12 months.

  Completion occurred on 23 June 2026. As the founders of the subsidiary continue to contribute to RocketDNA and are taking their consideration in escrowed equity, the transaction further aligns long-standing operators of the business with RocketDNA shareholders.

Risk Management

The Board continues to monitor and manage key business risks, within a risk management framework which can be summarised as:

- Zero target appetite risks, such as safety, fraud, and data and equipment protection.
- Strategic risks, such as staff retention and engagement, market and product developments, regulation and financial.
- External risks, such as overseas political risks, inflation, exchange rate and customer and supplier credit risk.

Outlook

RocketDNA enters the second half of FY26 with its flagship BMA deployment operating at scale, a growing base of enterprise customers, and continued rollout of the Skylink® operating system.

For personal use only

Key priorities for the coming quarters include:

- deepening utilisation of xBot® systems across existing customer sites and increasing recurring revenue per site
- continued rollout of Skylink® and expansion of SiteTube® capabilities
- advancing the Deswik software integration through technical scoping and toward a potential commercial arrangement
- progressing additional enterprise opportunities across mining and adjacent sectors in Australia and Africa
- continuing to assess corporate and strategic opportunities that could complement the existing business and support top-line growth.

The Company remains focused on leveraging its integrated hardware, software and data ecosystem to drive scalable, recurring revenue growth.

Significant changes in the state of affairs

There were no significant changes in the state of affairs of the Group during the half year ended 30 June 2026.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this Directors' report.

This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the Directors



Christopher Clark
Chief Executive Officer

18 August 2026

For personal use only

HALL CHADWICK

AUDITOR'S INDEPENDENCE DECLARATION
ROCKETDNA LTD AND ITS CONTROLLED ENTITIES

In accordance with section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of RocketDNA Ltd and its controlled entities.

As lead audit partner for the review of the financial report of RocketDNA Ltd and its controlled entities for the half-year ended 30 June 2026, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- any applicable code of professional conduct in relation to the review.

HALL CHADWICK AUDIT (WA) PTY LTD
ABN 42 163 529 682

NIKKI SHEN CA
Director

Dated this 18th day of August 2026
Perth, Western Australia

For personal use only

RocketDNA Ltd.
Contents
30 June 2026

Consolidated statement of profit or loss and other comprehensive income	7
Consolidated statement of financial position	8
Consolidated statement of changes in equity	9
Consolidated statement of cash flows	10
Notes to the consolidated financial statements	11
Directors' declaration	21
Independent auditor's review report to the members of RocketDNA Ltd.	22

General information

RocketDNA Ltd. is a listed public company limited by shares, incorporated and domiciled in Australia. A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of Directors, on 18 August 2026.

For personal use only

RocketDNA Ltd.
Consolidated statement of profit or loss and other comprehensive income
For the half-year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Revenue	3	4,997,631	3,326,235
Cost of sales		(3,029,833)	(1,794,817)
Gross profit		1,967,798	1,531,418
Other income		7,368	1,098
Gains from disposals of assets		63,559	26,872
Expenses			
Operating expense		(3,079,378)	(2,503,094)
Impairment	4	-	2,460
Depreciation expense		(200,065)	(175,617)
Amortisation of intangible assets		(131,317)	(46,270)
Operating loss		(1,372,035)	(1,163,133)
Finance income		27,182	10,701
Finance expense	5	(57,084)	(84,781)
Loss before income tax expense		(1,401,937)	(1,237,213)
Income tax expense		(33,464)	(17,704)
Loss after income tax expense for the half-year		(1,435,401)	(1,254,917)
Other comprehensive (loss)/income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		(127,850)	83,313
Other comprehensive (loss)/income for the half-year, net of tax		(127,850)	83,313
Total comprehensive loss for the half-year		(1,563,251)	(1,171,604)
Loss for the half-year is attributable to:			
Non-controlling interest		149,352	10,955
Owners of RocketDNA Ltd.		(1,584,753)	(1,265,872)
		(1,435,401)	(1,254,917)
Total comprehensive loss for the half-year is attributable to:			
Non-controlling interest		139,237	43,811
Owners of RocketDNA Ltd.		(1,702,488)	(1,215,415)
		(1,563,251)	(1,171,604)
		Cents	**Cents**
Basic loss per share	10	(0.13)	(0.14)
Diluted loss per share	10	(0.13)	(0.14)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

For personal use only

RocketDNA Ltd.
Consolidated statement of financial position
As at 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Assets			
Current assets			
Cash and cash equivalents		2,697,635	3,861,864
Trade and other receivables		1,861,693	2,770,415
Inventories		376,985	566,204
Deposits		29,876	31,005
Total current assets		4,966,189	7,229,488
Non-current assets			
Property, plant and equipment		2,292,390	2,085,166
Right-of-use assets		454,648	568,087
Intangibles		602,427	455,010
Deferred tax		2,287	31,425
Goodwill	6	1,007,117	1,022,708
Total non-current assets		4,358,869	4,162,396
Total assets		9,325,058	11,391,884
Liabilities			
Current liabilities			
Trade and other payables		1,629,422	1,508,119
Contract liabilities		128,692	482,640
Borrowings		174,255	322,930
Lease liabilities		237,308	307,138
Income tax		13,379	170,794
Total current liabilities		2,183,056	2,791,621
Non-current liabilities			
Borrowings		329,110	393,741
Lease liabilities		651,879	600,659
Total non-current liabilities		980,989	994,400
Total liabilities		3,164,045	3,786,021
Net assets		6,161,013	7,605,863
Equity			
Issued capital	7	22,384,099	21,289,405
Reserves	8	(747,100)	(653,073)
Accumulated losses		(15,412,897)	(12,771,709)
Equity attributable to the owners of RocketDNA Ltd.		6,224,102	7,864,623
Non-controlling interest		(63,089)	(258,760)
Total equity		6,161,013	7,605,863

For personal use only

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

RocketDNA Ltd.
Consolidated statement of changes in equity
For the half-year ended 30 June 2026

Consolidated	Issued capital $	Foreign currency translation reserve $	Reserves $	Share based payment reserve $	Accumulated losses $	Non-controlling interest $	Total equity $
Balance at 1 January 2025	17,144,970	(299,497)	(968,570)	258,310	(9,956,330)	(327,591)	5,851,292
(Loss)/profit after income tax expense for the half-year	-	-	-	-	(1,265,872)	10,955	(1,254,917)
Other comprehensive income for the half-year, net of tax	-	50,457	-	-	-	32,856	83,313
Total comprehensive (loss)/income for the half-year	-	50,457	-	-	(1,265,872)	43,811	(1,171,604)
Share based payments	-	-	-	(83,630)	-	-	(83,630)
Issue of shares	400,000	-	-	-	-	-	400,000
Share issue costs	(19,093)	-	-	-	-	-	(19,093)
Balance at 30 June 2025	17,525,877	(249,040)	(968,570)	174,680	(11,222,202)	(283,780)	4,976,965

Consolidated	Issued capital $	Foreign currency translation reserve $	Reserves $	Share based payment reserve $	Accumulated losses $	Non-controlling interest $	Total equity $
Balance at 1 January 2026	21,289,406	(126,627)	(968,570)	442,124	(12,771,710)	(258,760)	7,605,863
(Loss)/profit after income tax expense for the half-year	-	-	-	-	(1,584,753)	149,352	(1,435,401)
Other comprehensive loss for the half-year, net of tax	-	(117,735)	-	-	-	(10,115)	(127,850)
Total comprehensive (loss)/income for the half-year	-	(117,735)	-	-	(1,584,753)	139,237	(1,563,251)
Acquisition of non-controlling interest	1,000,000	-	-	-	(1,056,434)	56,434	-
Share based payments	-	-	-	23,708	-	-	23,708
Issue of shares	131,500	-	-	-	-	-	131,500
Share issue costs	(36,807)	-	-	-	-	-	(36,807)
Balance at 30 June 2026	22,384,099	(244,362)	(968,570)	465,832	(15,412,897)	(63,089)	6,161,013

For personal use only

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

RocketDNA Ltd.
Consolidated statement of cash flows
For the half-year ended 30 June 2026

	Note	Consolidated 2026 $	Consolidated 2025 $
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		5,820,109	3,712,103
Payments to suppliers (inclusive of GST)		(5,648,908)	(4,522,299)
		171,201	(810,196)
Interest received		27,188	10,603
Other revenue		1,518	1,376
Income taxes paid		(77,233)	(45,243)
Net cash from/(used in) operating activities		122,674	(843,460)
Cash flows from investing activities			
Payments for property, plant and equipment		(906,205)	(1,164,305)
Payments for intangibles		(236,091)	(130,092)
Other		(3,968)	2,719
Proceeds from disposal of property, plant and equipment		53,260	30,955
Net cash used in investing activities		(1,093,004)	(1,260,723)
Cash flows from financing activities			
Proceeds from issue of shares	7	-	400,000
Proceeds from borrowings		198,777	293,910
Share issue transaction costs		(37,301)	(37,127)
Repayment of borrowings		(340,548)	(278,290)
Net cash from/(used in) financing activities		(179,072)	378,493
Net decrease in cash and cash equivalents		(1,149,402)	(1,725,690)
Cash and cash equivalents at the beginning of the financial half-year		3,861,864	3,406,056
Effects of exchange rate changes on cash and cash equivalents		(14,827)	64,362
Cash and cash equivalents at the end of the financial half-year		2,697,635	1,744,728

For personal use only

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Material accounting policy information

Going concern
During the period, the Group generated a loss after tax from continuing operations of $1,435,401 (2025: $1,254,917), is reporting a net working capital of $2,783,132 (2025 : $4,437,867), has incurred net cash inflow from operations of $122,674 (2025 outflow of $843,460). As at 30 June 2026, the Group had $2,697,635 in cash (2025 : $3,861,864) and consolidated net assets of $6,161,013 (2025 : $7,605,863).

The Group has prepared the financial statements for the financial period ended 30 June 2026 on a going concern basis, which assumes continuity of current business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.

Note 2. Operating segments

Identification of reportable operating segments
The Group is organised into 3 continuing operating segments. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM)) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments. The segments are aligned with the geographical locations of the Group's main business, namely Australia and Africa.

Operating segment information

Consolidated - 2026	**Australia** $	**Africa** $	**Corporate** $	**Total** $
Income				
Revenue from external customers	2,589,367	2,408,264	-	4,997,631
Other income	7,368	-	-	7,368
Gain on sale of assets	51,567	11,992	-	63,559
Total income	2,648,302	2,420,256	-	5,068,558
EBITDA	(117,723)	386,280	(799,564)	(531,007)
Depreciation and amortisation	(478,815)	(291,899)	(70,314)	(841,028)
Finance income and expense	(29,366)	(1,357)	821	(29,902)
(Loss)/profit before income tax expense	(625,904)	93,024	(869,057)	(1,401,937)
Income tax expense				(33,464)
Loss after income tax expense				(1,435,401)

	Australia	Africa	Corporate	Total
Segment assets	3,575,113	3,560,324	2,189,621	9,325,058
Segment liabilities	1,811,140	737,383	615,522	3,164,045

For personal use only

Note 2. Operating segments (continued)

Consolidated - 2025	Australia $	Africa $	Corporate $	Total $
Income				
Revenue from external customers	980,788	2,345,447	-	3,326,235
Other income	-	1,098	-	1,098
Gain on sale of assets	8,694	18,178	-	26,872
Total income	989,482	2,364,723	-	3,354,205
EBITDA	(486,263)	433,379	(535,676)	(588,560)
Depreciation and amortisation	(162,177)	(353,029)	(61,826)	(577,032)
Impairment	2,460	-	-	2,460
Finance income and expense	(26,776)	(51,555)	4,250	(74,081)
(Loss)/profit before income tax expense	(672,756)	28,795	(593,252)	(1,237,213)
Income tax expense				(17,704)
Loss after income tax expense				(1,254,917)

	Australia	Africa	Corporate	Total
Segment assets	2,539,873	3,077,414	2,479,645	8,096,932
Segment liabilities	1,304,563	1,230,721	584,682	3,119,966

Note 3. Revenue

	Consolidated 2026 $	Consolidated 2025 $
Timing of revenue recognition		
At a point in time	1,565,314	1,121,364
Over time	3,432,317	2,204,871
	4,997,631	3,326,235

Note 4. Impairment

The loss allowance for trade receivables as at 30 June 2026 reconciled to the opening loss allowance as follows:

	Consolidated 2026 $	Consolidated 2025 $
Credit loss release of provision recognised through P&L	-	(2,460)

For personal use only

Note 5. Finance expense

	Consolidated 2026 $	Consolidated 2025 $
Interest on motor vehicle and equipment leases	39,891	43,936
Interest on liabilities relating to right-of-use assets	8,321	19,887
Realised and unrealised foreign currency (gains)/losses	8,872	20,958
	57,084	84,781

Note 6. Non-current assets - Goodwill

	Consolidated 2026 $	Consolidated 2025 $
Goodwill	1,007,117	1,022,708

Goodwill relates to the acquisition of Africa, and RocketDNA (WA) Pty Ltd (formerly Rocketmine WA Pty Ltd or Arvista Pty Ltd). The recoverable amount of all cash-generating units is based on the higher of its value-in-use or fair value less costs to sell which require use of assumptions. For the purpose of impairment testing, goodwill is allocated to two (2) cash-generating units (CGU), being Africa and, from 24 June 2026, Australia, after the acquisition of the remaining non-controlling interest relating to RocketDNA (WA) Pty Ltd. In assessing goodwill impairment for the period ended 30 June 2026, both CGUs used a discounted cash flow model in accordance with the value-in-use (VIU) method, which reflect the present value of the future cash flows to be derived from each CGUs.

Note 7. Equity - issued capital

	Consolidated 2026 Shares	Consolidated 2025 Shares	Consolidated 2026 $	Consolidated 2025 $
Ordinary shares - fully paid	1,235,075,487	1,182,189,898	22,384,099	21,289,40

Movements in ordinary share capital

Details	Date	Shares	Issue price	$
Balance	1 January 2026	1,182,189,898		21,289,406
Employee incentive shares	7 January 2026	617,984	$0.0259	16,000
KMP performance rights exercised	24 March 2026	10,500,000	$0.0110	115,500
Acquisition of non-controlling interest	22 June 2026	41,767,605	$0.0239	1,000,000
Share issue costs				(36,807)
Balance	30 June 2026	1,235,075,487		22,384,099

Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back
There is no current on-market share buy-back.

For personal use only

Note 7. Equity - issued capital (continued)

Acquisition of non-controlling interest
On 22 June 2026, RocketDNA Ltd acquired the remaining 40% of RocketDNA (WA) Pty Ltd that it did not previously own. Rocket DNA now holds 100% of RocketDNA (WA). The consideration was A$1.0 million, satisfied entirely in new fully paid ordinary RocketDNA shares (no cash) priced at the 20-day volume weighted average price (VWAP) of RocketDNA shares up to 15 June 2026, being $0.023942. The Company issued 41,767,605 shares, or approximately 3.5% of the current issued capital. As control already existed, the transaction was accounted for as an equity transaction.

	Shares	$
Consideration paid for remaining 40% of RocketDNA (WA) Pty Ltd	41,767,605	1,000,000
Carrying amount of NCI for RocketDNA (WA) Pty Ltd on 22 June 2026		56,434
Difference recognised directly in equity		1,056,434

Note 8. Equity - reserves

	Consolidated 2026 $	Consolidated 2025 $
Predecessor accounting reserves	(968,570)	(968,570)
Foreign currency translation reserve	(244,362)	(126,627)
Share-based payments reserve	465,832	442,124
	(747,100)	(653,073)

Foreign currency translation reserve
The reserve is used to recognise exchange differences arising from the translation of the financial statements of foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net investments in foreign operations.

Share-based payments reserve
The reserve is used to recognise the value of equity benefits provided to employees and Directors as part of their remuneration, and other parties as part of their compensation for services.

Predecessor accounting reserve
The predecessor accounting reserve comprises the excess of purchase price over the fair value of net assets when the common controlled entity, RocketDNA Training and Consulting (Pty) Ltd was acquired by Delta Drone SA France.

Note 9. Events after the reporting period

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

For personal use only

Note 10. Earnings per share

	Consolidated 2026 $	Consolidated 2025 $
Loss after income tax	(1,435,401)	(1,254,917)
Non-controlling interest	(149,352)	(10,955)
Loss after income tax attributable to the owners of RocketDNA Ltd.	(1,584,753)	(1,265,872)
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	1,190,360,287	907,620,758
Weighted average number of ordinary shares used in calculating diluted earnings per share	1,190,360,287	907,620,758
	Cents	**Cents**
Basic loss per share	(0.13)	(0.14)
Diluted loss per share	(0.13)	(0.14)

For personal use only

Note 11. Share-based payments

During the half-year, the group provided shares and performance rights to African and Australian employees as part of its employee share plans; and provided performance rights to Directors as part of their remuneration package. Share options were also provided to third parties. Details of the share-based payments provided for the half-year to 30 June 2026 are:

The details of the share-based payments provided during the period are:

	Recipient	Instrument	Number	Conditions	Grant Date	Recognition	Fair Value
(i)	Christopher Clark	Performance Rights	20,000,000	2027 milestones	28 May 2026	50% pro-rata to 31 Dec 2027	2.3c per right
(ii)	Paul Williamson	Performance Rights	10,000,000	2027 Milestones	28 May 2026	50% pro-rata to 31 Dec 2027	2.3c per right
(iii)	Australian employees	Performance Rights	1,500,000	2027 Milestones	30 May 2025	50% pro-rata to 31 Dec 2027	2.1c per right
(iv)	Australian employees	Performance Rights	7,500,000	future employment	1 Jan 2026 & 31 May 2026	Pro-rata to over 12, 24 and 36 months	2.0c /2.1c per right
(v)	African employees	Performance Rights	1,500,000	future employment	31 May 2026	Pro-rata to over 12, 24 and 36 months	2.1c per right
(vi)	Third party provider	Share options	5,000,000	continued engagement	19 Jan 2026	Pro-rata to 1 July 2026	0.1c per option

(i), (ii) (iii) Vesting of 2027 performance rights are conditional and variable based on 2 milestones which run to 31 December 2027. The performance rights were issued at nil cost and will be converted into the equivalent number of shares when exercised. All performance rights are valued at the market price of the underlying shares on the date of grant.

(vi) The share options granted on 19 January 2025 were valued using the Hoadley Trading and Investment Tools ESO2 valuation model at the fair value shown in table above.

For personal use only

Note 11. Share-based payments (continued)

In addition to the share-based payments provided during the year, there was a change in the accounting estimate for recognition of the performance rights issued on 30 May 2025, which reached the end of the qualifying period without meeting 2025 Milestones 2 and 3 and will now be forfeited.

	Recipient	Instrument	Original number granted and previous vesting estimate	Grant Date	Conditions	Last qualifying financial period	Recognition as at 31 December 2024	Revised recognition	Fair Value
(vii)	Christopher Clark	Performance Rights	6,000,000	30 May 2025	2025 Milestones 2 and 3	Year to 30 June 2026	Pro-rata to 30 June 2026	Nil	-
(viii)	Paul Williamson	Performance Rights	3,000,000	25 May 2023	2025 Milestones 2 and 3	Year to 30 June 2026	Pro-rata to 31 Dec 2025	Nil	-

Details of the share-based payment recognition for existing instruments, which had no change in recognition estimates, are set out below:

	Recipient	Instrument	Number	Conditions	Grant Date	Recognition	Fair Value
(ix)	Christopher Clark	Performance Rights	3,000,000	2023 Milestone 1	25 May 2023	Pro-rata to 31 Dec 2026	1.1c per right
(x)	Paul Williamson	Performance Rights	1,500,000	2023 Milestone 1	25 May 2023	Pro-rata to 31 Dec 2026	1.1c per right
(xi)	Christopher Clark	Share Options	30,000,000	Future employment	30 May 2025	Pro-rata to vesting dates	0.61c, 0.63c 0.66c per option
(xii)	Paul Williamson	Share Options	15,000,000	Future employment	30 May 2025	Pro-rata to various dates	0.61c, 0.63c 0.66c per option
(xiii)	David Morton	Share options	15,000,000	Future employment	30 May 2025	Pro-rata to various dates	0.61c, 0.63c 0.66c per option
(xiv)	Advisory Board members	Share options	6,000,000	Escrow to 1 June 2027	16 July 2025	Pro-rata to various dates	0.71c per option
(xv)	Australian employees	Share options	2,500,000	Future employment	31 July 2025	Pro-rata to various dates	0.6c per. option
(xvi)	African employees	Share options	6,500,000	Future employment	31 July 2025	Pro-rata to various dates	0.59c, 0.63c 0.65c per option

For personal use only

Note 11. Share-based payments (continued)

The movement in holdings of performance rights during the year were:

Name	Milestones	No. of Performance Rights held as at 31 December 2025	Granted during the period	Vested and exercised during the period	No. of Performance Rights as at 30 June 2026
Christopher Clark	2022 New Milestones	8,000,000	-	-	8,000,000
Christopher Clark	2023 New Milestones	6,000,000	-	(3,000,000)	3,000,000
Christopher Clark	2025 New Milestones*	10,000,000	-	(4,000,000)	6,000,000
Christopher Clark	2027 Milestones	-	20,000,000	-	20,000,000
Paul Williamson	2022 New Milestones	4,000,000	-	-	4,000,000
Paul Williamson	2023 New Milestones	3,000,000	-	(1,500,000)	1,500,000
Paul Williamson	2025 New Milestones*	5,000,000	-	(2,000,000)	3,000,000
Paul Williamson	2027 Milestones	-	10,000,000	-	10,000,000
Total		36,000,000	30,000,000	(10,500,000)	55,500,000

*The remaining 2025 milestones were not achieved, as required, by 30 June 2026 and hence these performance rights will be forfeited in the second half of 2026.

2022 New Milestones

Milestone	Description
New Milestone 1	The Group achieving total consolidated EBIT of not less than A$nil (i.e. break-even) in a single financial year (being 1 Jan to 31 Dec) based on audited accounts having been prepared by an external auditor or other suitable expert.
New Milestone 2	The Group achieving total consolidated revenue of not less than A$15,000,000 in a single financial year (being 1 Jan to 31 Dec) based on audited accounts having been prepared by an external auditor or other suitable expert.
New Milestone 3	The Group achieving total consolidated EBIT of more than A$2,000,000 in a single financial year (being 1 Jan to 31 Dec) based on audited accounts having been prepared by an external auditor or other suitable expert.

2023 New Milestone remaining

Milestone	Description
Milestone 1	Reaching operating cashflow break even as measured by the total of four consecutive positive quarters as disclosed in the Company's ASX Appendix 4C item 1.9, excluding revenue received in the form of government grants, allowances, rebates or other hand-outs.

For personal use only

Note 11. Share-based payments (continued)

2027 Milestones	Description
Milestone 1 Revenue Growth	There must be minimum Revenue Growth (RG) of 40% over a prior comparable period before any Performance Rights (RG Rights) vest. If Revenue Growth is 40% then 30% of the RG Rights will vest. For every 1% of Revenue Growth above 30%, an additional 0.5% of the RG Rights will vest, up to 100% growth. Beyond 100% growth, for every 6% growth, an additional 5% of the RG Rights will vest, until the maximum number of RG Rights have vested. For example, if Revenue Growth is 100%, 60% of the RG Rights will vest; if Revenue Growth is 130%, 85% of the RG Rights will vest. The maximum number of RG Rights (i.e 100% of the RG Rights) will vest if Revenue Growth is 148%. For the purposes of this milestone, Revenue Growth is defined as the increase in the groups consolidated revenue over the prior comparable period (PCP) as a percentage of the PCP revenue. (i) one-off or extraordinary revenue items: (ii) revenue received in the form of government grants, allowances, rebates and other handouts; and (iii) revenue or profit items that have been 'manufactured' to achieve the Milestone. For the purposes of this Milestone, the comparison periods are: (i) the audited full financial year ending 31 December 2026 compared with the audited full financial year ending 31 December 2025; or (ii) the audited or reviewed half-year ending 30 June 2027 compared with the audited or reviewed half-year ending 30 June 2026; or (iii) the audited full financial year ending 31 December 2027 compared with the audited full financial year ending 31 December 2026. RG Rights may vest for more than one of these periods, but the total aggregate RG Rights vesting across all periods cannot exceed 100% of the RG Rights.
Milestone 2 Total Shareholder Return	There must be a minimum growth in Total Shareholder Return (TSR) of 50% over the TSR Measurement Period before any Performance Rights (TSR Rights) vest. The maximum number of TSR Rights will vest if the TSR reaches 150% in the TSR Measurement Period. If within the TSR Measurement Period the TSR is 50% then 25% of the TSR Rights will vest. For every 1% change in the TSR above 50%, an additional 0.75% of the TSR Rights will vest until the maximum number of TSR Rights have vested. For the purposes of this Milestone: (i) TSR Measurement Period means the period commencing on 1 July 2026 and ending on 31 December 2027. (ii) Base Price means the volume-weighted average price (VWAP) of the Company's shares calculated over the 20 trading days immediately prior to and including 1 July 2026. (iii) Milestone Price means the highest VWAP of the Company's shares calculated over any 20 consecutive trading days during the TSR Measurement Period, to be calculated following the end of the TSR Measurement Period. (iv) TSR is calculated as: TSR = (Milestone Price - Base Price) + Dividends per share (if any) declared and paid during the TSR Measurement Period/ Base Price x 100. All fractions are rounded down to the nearest one percent. (v) For the purposes of determining the VWAP, trading excludes block trades, large portfolio trades, permitted trades

For personal use only

Note 11. Share-based payments (continued)

Reconciliation of expense and share-based payment reserve

During the year to 30 June 2026, the charge recognised with in Employee costs in the statement of profit and loss, was $155,208 (2025: $83,631 credit). The charge is composed:

Recognition of pro-rata expense for performance rights granted to KMP on 28 May 2026	(i) (ii)	19,562
Recognition of pro-rata expense for performance rights granted to employees in 2026	(iii) (iv) (v)	34,248
Recognition of expense for share options issued to third parties on 19 January 2026	(vi)	49,691
Re-estimation of cumulative expense for performance rights granted on 30 May 2025	(vii) (viii)	(35,680)
Pro-rata expense for performance rights granted 25 May 2023	(ix) (x)	6,808
Pro-rata expense for share options issued to KMP on 30 May 2025	(xi) (xii) (xiii)	67,160
Pro-rata expense for share options issued to Advisory Board members on 16 July 2025	(xiv)	11,403
Pro-rata expense for share options issued to employees prior to 1 January 2026	(xv) (xvi)	2,928
Other adjustments to previous recognition		(912)
Total share-based payments recognised during the half-year to 30 June 2026		**155,208**

Share-based payments recognised cumulatively to 31 December 2025	656,624
Total share-based payments recognised during the half-year to 30 June 2026 (above)	155,208
Share-based payments recognised cumulatively to 30 June 2026	811,832
Shares issued under all schemes to date	(346,000)
Share-based payment reserve as at 30 June 2026	**465,832**

Share-based payment reserve as at 31 December 2025	442,124
Total share-based payments recognised during the half-year to 30 June 2026 (above)	155,208
Shares issued under employee schemes during the half-year to 30 June 2026	(16,000)
Shares issued on 24 March 2026 re. KMP performance rights exercised	(115,500)
Share-based payment reserve as at 30 June 2026	**465,832**

Notes (i) to (xvi) refer to the detailed information provided above.

For personal use only

RocketDNA Ltd.
Directors' declaration
30 June 2026

In the Directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;

- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial half-year ended on that date; and

- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of Directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the Directors



Christopher Clark
Chief Executive Officer

18 August 2026

For personal use only

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF ROCKETDNA LTD

Conclusion

We have reviewed the accompanying half-year financial report of RocketDNA Ltd ("the Company") and Controlled Entities ("the Consolidated Entity") which comprises the condensed consolidated statement of financial position as at 30 June 2026, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, a summary of material accounting policies and other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of RocketDNA Ltd and its controlled entities do not comply with the *Corporations Act 2001* including:

a. Giving a true and fair view of the Consolidated Entity's financial position as at 30 June 2026 and of its performance for the half-year ended on that date; and

b. Complying with Accounting Standard AASB 134: *Interim Financial Reporting* and *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity.* Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's review report.

Responsibility of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

For personal use only

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Consolidated Entity's financial position as at 30 June 2026 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB *134 Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

HALL CHADWICK AUDIT (WA) PTY LTD

NIKKI SHEN CA
Director

Dated 18th day of August 2026
Perth, Western Australia

For personal use only